Laboratory Corporation of America Holdings (LH) Stock

At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. At the same time, we keep an eye on the most recent trends in value, growth, and momentum to support our top selections.

Investors are becoming more positive about LH because of its emphasis on areas with high growth potential and its strategic collaborations.

LH has announced a strategic partnership with Graves Gilbert Clinic to manage lab operations.

LH has launched a new H5 bird flu test, created in partnership with the CDC, and it is now accessible in the United States.

A new test has been developed to help with public health readiness and testing systems during a multistate outbreak of H5 bird flu in birds and dairy cows. Labcorp, a leading laboratory services company, announced on December 17, 2024, that its new H5 bird flu molecular test is now available for diagnosing human infections.

In my first analysis of Labcorp, I recommend holding onto the stock, as it offers a chance to receive a quarterly dividend of $0.72 per share from a top clinical lab company in the US. The company is showing signs of future growth with new locations and acquisitions, along with an anticipated increase in patient demand for diagnostics. However, Labcorp faces challenges with a low profit margin and rising expenses compared to its main competitor, Quest Diagnostics.

The private equity company Cinven has received conditional approval from Italian officials for its plan to sell a 15% share in the diagnostic service provider Synlab to the laboratory operator Labcorp, according to a government document presented to parliament.

Investors are becoming more positive about LH because of its collaborations and strong management practices.

Labcorp Holdings Inc. (NYSE:LH) will hold its Q3 2024 Earnings Conference Call on October 24, 2024, at 9:00 AM ET. Key participants from the company include Christin O'Donnell, Adam Schechter, and Glenn Eisenberg. Various analysts from firms like Mizuho, JPMorgan, and Citi will also be joining the call.